{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:39:49Z","timestamp":1790732389943,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-030"],"award-info":[{"award-number":["2021-I2M-1-030"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.apsb.2023.08.030","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T01:29:39Z","timestamp":1694222979000},"page":"4945-4962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Discovery and druggability evaluation of pyrrolamide-type GyrB\/ParE inhibitor against drug-resistant bacterial infection"],"prefix":"10.1016","volume":"13","author":[{"given":"Xintong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunsheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangfan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1696-6208","authenticated-orcid":false,"given":"Fangfang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyilan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.08.030_bib1","article-title":"Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations","author":"O'neill","year":"2014","journal-title":"Review on Antimicrobial Resistance"},{"key":"10.1016\/j.apsb.2023.08.030_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.08.030_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41570-021-00313-1","article-title":"Towards the sustainable discovery and development of new antibiotics","volume":"5","author":"Miethke","year":"2021","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: past, present and future","volume":"51","author":"Hutchings","year":"2019","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.apsb.2023.08.030_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.sbi.2012.11.011","article-title":"New insights into DNA-binding by type IIA topoisomerases","volume":"23","author":"Chang","year":"2013","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.apsb.2023.08.030_bib6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2174\/0929867324666171106160326","article-title":"New Strategy on antimicrobial-resistance: inhibitors of DNA replication enzymes","volume":"26","author":"Yi","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/41483","article-title":"The complete genome sequence of the gastric pathogen Helicobacter pylori","volume":"388","author":"Tomb","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.030_bib8","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.47.3.869-877.2003","article-title":"Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocin","volume":"47","author":"Schmutz","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2023.08.030_bib9","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1073\/pnas.73.11.3872","article-title":"DNA gyrase: an enzyme that introduces superhelical turns into DNA","volume":"73","author":"Gellert","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.08.030_bib10","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00018-010-0299-5","article-title":"In front of and behind the replication fork: bacterial type IIA topoisomerases","volume":"67","author":"Sissi","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2023.08.030_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112326","article-title":"Recent advances in DNA gyrase-targeted antimicrobial agents","volume":"199","author":"Dighe","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bioorg.2015.07.004","article-title":"Dual targeting DNA gyrase B (GyrB) and topoisomerase IV (ParE) inhibitors: a review","volume":"62","author":"Azam","year":"2015","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib13","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.apsb.2023.08.030_bib14","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.3390\/molecules25235662","article-title":"Quinolones: mechanism, lethality and their contributions to antibiotic resistance","volume":"25","author":"Bush","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.08.030_bib15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(56)90052-6","article-title":"Two new antibiotics: antibacterial activity of novobiocin and vancomycin","volume":"268","author":"Fairbrother","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.08.030_bib16","first-page":"209","article-title":"Microbiological and\u00a0pharmacological evaluation of BL-C43, a new semisynthetic derivative of coumermycin A1","volume":"9","author":"Price","year":"1969","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2023.08.030_bib17","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/j.1460-2075.1996.tb00483.x","article-title":"The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines was revealed by X-ray crystallography","volume":"15","author":"Lewis","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2023.08.030_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A new-class antibacterial-almost. lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2023.08.030_bib19","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4155\/fmc-2017-0257","article-title":"Recent progress in the discovery and development of DNA gyrase B inhibitors","volume":"10","author":"Barancokov","year":"2018","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/13543776.2019.1575362","article-title":"ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents","volume":"29","author":"Durcik","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2023.08.030_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104266","article-title":"Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors","volume":"104","author":"Jaswal","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib22","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.2174\/1871529X21666210202113128","article-title":"Recent progress in small molecular inhibitors of DNA Gyrase","volume":"28","author":"Man","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib23","doi-asserted-by":"crossref","first-page":"01208","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2023.08.030_bib24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2023.08.030_bib25","doi-asserted-by":"crossref","first-page":"02537","DOI":"10.1128\/AAC.02537-17","article-title":"Phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DS-2969b, a novel GyrB inhibitor, in healthy subjects","volume":"62","author":"Vandell","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2023.08.030_bib26","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1021\/jm500462x","article-title":"Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)","volume":"57","author":"Basarab","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib27","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.1016\/j.bmcl.2011.10.010","article-title":"Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy","volume":"21","author":"Sherer","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2023.08.030_bib28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.chembiol.2011.06.011","article-title":"Discovery of kibdelomycin, a potent new class of bacterial Type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus","volume":"18","author":"Phillips","year":"2011","journal-title":"Chem Biol"},{"key":"10.1016\/j.apsb.2023.08.030_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113200","article-title":"New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens","volume":"213","author":"Durcik","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib30","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/acs.jmedchem.2c01597","article-title":"Discovery and hit-to-lead optimization of benzothiazole scaffold based DNA gyrase inhibitors with potent activity against Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"66","author":"Cotman","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.030_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4161\/viru.26083","article-title":"Animal models of sepsis","volume":"5","author":"Fink","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.apsb.2023.08.030_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2017.09.004","article-title":"In\u00a0vivo infection models in the pre-clinical pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents","volume":"36","author":"Andes","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.apsb.2023.08.030_bib33","doi-asserted-by":"crossref","first-page":"iv23","DOI":"10.1093\/jac\/dkab352","article-title":"Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections","volume":"76","author":"Bassetti","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2023.08.030_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nature22308","article-title":"Predictive compound accumulation rules yield a broad-spectrum antibiotic","volume":"545","author":"Richter","year":"2017","journal-title":"Nature"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523003374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523003374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:04:13Z","timestamp":1761930253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523003374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2211383523003374"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.08.030","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and druggability evaluation of pyrrolamide-type GyrB\/ParE inhibitor against drug-resistant bacterial infection","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}